BLACKWOOD, N.J.–(BUSINESS WIRE)–U.S.Vision has announced a temporary program to help Florida residents in the wake of Hurricane Ian’s destruction in that state’s southwest region.
Category: Business
VECT-HORUS RECOIT UNE SUBVENTION POUR LE DEVELOPPEMENT DE SA PLATEFORME VECTRANS® DANS LE DOMAINE DE L’OPHTALMOLOGIE
MARSEILLE, France–(BUSINESS WIRE)–Vect-Horus, une société de biotechnologie qui conçoit et développe des vecteurs permettant l’adressage ciblé de molécules thérapeutiques et d’agents d’imagerie vers différents organes dont le cerveau, annonce l’accor…
Santen Announces Health Canada Approval for Cationorm® Plus to Relieve the Symptoms of Dry Eye and Ocular Allergy
TORONTO–(BUSINESS WIRE)–Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), today announced the approval of Cationorm® Plus by Health Canada. Cationorm® Plus is a unique hydrating artificial tear that restores moisture in th…
Santen annonce l’approbation de CationormMD Plus pour soulager les symptômes de la sécheresse et l’allergie oculaires
TORONTO–(BUSINESS WIRE)–Santen Canada Inc., filiale de Santen Pharmaceutical Co., Ltd. (« Santen »), a annoncé aujourd’hui l’approbation de CationormMD Plus par Santé Canada. CationormMD Plus est une solution unique de larmes artificielles qui restau…
Topcon Introduces NW500 Non-Mydriatic Retinal Camera
TOKYO–(BUSINESS WIRE)– #TopconHealthcare–Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, is pleased to announce that it has launched the NW500, its new fully-automatic, non-mydriatic…
Harrow Sells Non-Ophthalmic Compounding Business
NASHVILLE, Tenn.–(BUSINESS WIRE)—- $HROW–Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non‑ophth…
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an…
Zenni Surpasses 50 Million Pairs of Glasses Sold, New Mobile App Release Accelerates Growth for Online Eyewear Retail Pioneer
NOVATO, Calif.–(BUSINESS WIRE)–Zenni, the online eyewear retail leader, announced today it has recently eclipsed 50 million pairs of glasses sold since its launch in 2003, signaling its continued growth and ability to scale in a competitive market la…
Kubota Vision Announces Positive Post Hoc Analysis from Phase 3 Clinical Trial of Emixustat in Patients with Stargardt Disease
SEATTLE–(BUSINESS WIRE)–Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today positive results from a post hoc analysis of th…
New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics announced new data on the key drivers of Thyroid Eye Disease (TED) at the American Academy of Ophthalmology (AAO) 2022.
CXL Ophthalmics Announces $32 Million Series A Investment Round Led by AXA IM Alts, Through its Global Health Private Equity Strategy
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics today announced it has raised a $32 million Series A funding round led by AXA IM Alts plus a syndicate of individual investors.
Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study Data Showing Corneal Regeneration and Vision Recovery Following Descemet Stripping Only (DSO) Surgery
CHICAGO–(BUSINESS WIRE)–Trefoil Therapeutics today announced positive Phase 2 results for TTHX1114 in patients with Fuchs Endothelial Corneal Dystrophy.
CXL Ophthalmics Publishes Results of EpiSmart® Cross-Linking Phase 2 Clinical Trial for Keratoconus in Cornea
SHERBORN, Mass.–(BUSINESS WIRE)–CXL Ophthalmics today published results of the EpiSmart Cross-linking Phase 2 study for Keratoconus in Cornea.
InflammX Therapeutics Submits IND Amendment to Enable Clinical Studies with Orally Dosed Xiflam™, its NLRP3 Inflammasome-targeting Program in Retinal and Kidney Disease
TAMPA, Fla.–(BUSINESS WIRE)–InflammX Therapeutics, Inc. (InflammX), a privately held biopharmaceutical company, today announced the submission of an Investigational New Drug (IND) Amendment to U.S. Food and Drug Administration (FDA), to enable the co…
Ora, Inc. Launches the Ora EyecupTM, a Revolutionary Ophthalmic Research Technology at Eyecelerator 2022
BOSTON–(BUSINESS WIRE)–Ora, Inc., the world’s leading ophthalmology clinical research firm, has formally launched a revolutionary mobile research platform, Ora EyeCupTM, which promises to transform patient data capture through high-resolution imaging…
Visus Therapeutics Expands Ophthalmic Drug Development Portfolio With Acquisition of ViewPoint Therapeutics’ Assets
SEATTLE–(BUSINESS WIRE)– #presbyopia–Visus Therapeutics Inc. expanded its pipeline via the acquisition of all patents and other assets of ViewPoint Therapeutics, Inc.
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
MENLO PARK, Calif.–(BUSINESS WIRE)– #SeriesA–Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction
TEL AVIV, Israel & MELBOURNE, Australia–(BUSINESS WIRE)–Azura Ophthalmics provides update on AZR-MD-001 Phase 2 clinical program targeting Meibomian Gland Dysfunction.
Global Retinal Surgery Devices Market Analysis Report 2022-2027: Major Company Profiles, Deals, Strategies, Growth Drivers and Recent Developments – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Impact of COVID-19, Company Profiles, Major Deals, Strategy and Recent Developments – Forecast to 2027” report has been added to Re…
RetinAI Expands Operations with a U.S. Office In Boston and Achieves 21 CFR Part 11 Compliance to Support Research and Clinical Studies
BERN, Switzerland & BOSTON–(BUSINESS WIRE)– #AI–RetinAI Medical AG (“RetinAI”), is a leader in clinical and imaging data management software and advanced analytics for ophthalmology, is excited to announce the launch of its first U.S.-based office, …